Login to Your Account



Amgen a Possible Bidder?

A 'Hostile' Reaction? Genzyme Rebuffs Sanofi Offer, Officially

By Jennifer Boggs


Tuesday, August 31, 2010
It's about time. A month of rampant speculation fueled by a flurry of media reports citing unnamed sources finally culminated in Genzyme Corp.'s publicly acknowledged receipt of a $69-per-share buyout bid from Sanofi-Aventis SA, and the big biotech wasted no time rejecting the roughly $18.5 billion offer as too low. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription